Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of astragaloside IV in preparing liver cancer resisting medicines

A technology for astragalus saponins and medicines is applied in the application field of astragalus saponins IV in the preparation of anti-cancer drugs, and can solve the problems of control, difficult quality and stability, complex components and the like

Active Publication Date: 2013-03-20
CHIATAI QINGCHUNBAO PHARMA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In addition, astragalus polysaccharides, total saponins of astragalus, or astragalus injection are also complex in composition, making it difficult to control their quality and stability so that they can meet the requirements of modern medication

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of astragaloside IV in preparing liver cancer resisting medicines
  • Application of astragaloside IV in preparing liver cancer resisting medicines
  • Application of astragaloside IV in preparing liver cancer resisting medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Example 1 Preparation of Astragaloside II and IV

[0055] 1. Experimental materials

[0056] 1.1 Test drug Astragalus (origin Gansu, purchased from Guotou Pharmaceutical Anhui Co., Ltd., batch number: 080623; identified as Astragalus membranaceus by Professor Liu Shoujin, Department of Medicinal Botany, Anhui College of Traditional Chinese Medicine); Astragaloside IV standard product (China Pharmaceutical Biology Product Inspection Institute, batch number: 0781-200210); astragaloside Ⅱ standard product (provided by Shanghai Standardization Research Center of Traditional Chinese Medicine, batch number: 07-1015); high-efficiency silica gel G plate (Qingdao Ocean Chemical Factory); silica gel for column chromatography (Qingdao Ocean Chemical Group); D101 resin (Tianjin Youchang Industry and Trade Co., Ltd.); ethanol, n-butanol, ethyl acetate, and methanol are analytically pure, acetonitrile is chromatographically pure, and water is double distilled water.

[0057] 1.2 Apparatus ...

Embodiment 2

[0103] Example 2 Study on the anti-tumor effect of astragaloside Ⅱ and Ⅳ

[0104] 1. Experimental materials

[0105] 1.1. Cell lines Human liver cancer cell line BEL-7402 and liver cancer drug-resistant cell line BEL-7402 / 5-FU were purchased from Nanjing KGI Biotechnology Development Co., Ltd.

[0106] 1.2 Medicines and reagents

[0107] Astragaloside Ⅱ (AS Ⅱ), Astragaloside Ⅳ (AS Ⅳ) (laboratory self-made)

[0108] Right-handed verapamil (R(+)-VERAPAMIL HCL, VRP) was purchased from IL company in the United States, purity>99%

[0109] 5-FU Tianjin Jinyao Amino Acid Co., Ltd., batch number 0810211

[0110] MMC Zhejiang Hisun Pharmaceutical Co., Ltd., batch number 0810211

[0111] ADR Zhejiang Hisun Pharmaceutical Co., Ltd., batch number 0810211

[0112] DMEM and Fetal Bovine Serum American Gibco products

[0113] MTT American Sigma company product

[0114] DMSO American Sigma company product

[0115] Rho123 American Sigma company product

[0116] Trypsin BIOSHARP company product

[0117] PBS Boste...

Embodiment 3

[0249] Tablet: Astragaloside IV 10mg

[0250] Lactose 187mg

[0251] Corn starch 50mg

[0252] Magnesium stearate 3mg

[0253] Preparation method: mix the active ingredient, lactose and starch, moisten it evenly with water, sieve and dry the moistened mixture, sieve again, add magnesium stearate, then press the mixture into tablets, each tablet weighs 250 mg, and the active ingredient content It is 10mg.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical fields of traditional Chinese medicine active ingredient extraction and application. The astragaloside IV has obvious inhibition effect on proliferation of two human liver cancer cells, namely BEL-7402 and BEL-7402 / 5-FU under the condition of different concentrations, and can be administrated with other medicines simultaneously or sequentially to achieve the anti-tumor effect. The invention provides an anti-tumor medicine with definite response relationship and corroborant structural components, lays a foundation for developing new clinical anti-tumor medicines, provides a medicine for reversing multidrug resistance to achieve the anti-tumor effect, and provides a new scheme for solving the problem of multidrug resistance of chemotherapeutics.

Description

Technical field [0001] The invention relates to the technical field of extraction and application of effective components of traditional Chinese medicine. Specifically, it relates to the application of astragaloside IV in the preparation of anti-liver cancer drugs. Background technique [0002] Apoptosis and cell proliferation in a normal body always maintain a dynamic balance under tight control. Once this balance is broken, it will lead to the occurrence of many diseases. Due to the decline in apoptosis, mutant cells cannot be effectively eliminated and continue to accumulate. Tumor. Drugs that can induce apoptosis play an important role in tumor treatment. [0003] Multi-drug resistance (Mtltidrug Resistance, MDR) is the similarity in which tumor cells are induced by a drug to simultaneously develop cross-resistance to multiple chemotherapeutics with different structures and functions. The mechanism of tumor MDR is extremely complicated, and it is the result of multi-gene and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61P35/00
Inventor 许杜娟王培培高建
Owner CHIATAI QINGCHUNBAO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com